Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has received an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $2.32.
Separately, StockNews.com initiated coverage on Cara Therapeutics in a research note on Sunday. They issued a “sell” rating on the stock.
Read Our Latest Stock Report on Cara Therapeutics
Institutional Trading of Cara Therapeutics
Cara Therapeutics Price Performance
CARA opened at $0.27 on Wednesday. The stock has a market cap of $14.71 million, a PE ratio of -0.12 and a beta of 0.70. Cara Therapeutics has a 52 week low of $0.24 and a 52 week high of $1.40. The business’s fifty day simple moving average is $0.30 and its 200 day simple moving average is $0.45.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last released its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. As a group, equities analysts anticipate that Cara Therapeutics will post -1.24 earnings per share for the current year.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
See Also
- Five stocks we like better than Cara Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Short Selling: How to Short a Stock
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What is the Australian Securities Exchange (ASX)
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.